Literature DB >> 16474158

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Penny L Moore1, Emma T Crooks, Lauren Porter, Ping Zhu, Charmagne S Cayanan, Henry Grise, Paul Corcoran, Michael B Zwick, Michael Franti, Lynn Morris, Kenneth H Roux, Dennis R Burton, James M Binley.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies are thought be distinguished from nonneutralizing antibodies by their ability to recognize functional gp120/gp41 envelope glycoprotein (Env) trimers. The antibody responses induced by natural HIV-1 infection or by vaccine candidates tested to date consist largely of nonneutralizing antibodies. One might have expected a more vigorous neutralizing response, particularly against virus particles that bear functional trimers. The recent surprising observation that nonneutralizing antibodies can specifically capture HIV-1 may provide a clue relating to this paradox. Specifically, it was suggested that forms of Env, to which nonneutralizing antibodies can bind, exist on virus surfaces. Here, we present evidence that HIV-1 particles bear nonfunctional gp120/gp41 monomers and gp120-depleted gp41 stumps. Using a native electrophoresis band shift assay, we show that antibody-trimer binding predicts neutralization and that the nonfunctional forms of Env may account for virus capture by nonneutralizing antibodies. We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474158      PMCID: PMC1395414          DOI: 10.1128/JVI.80.5.2515-2528.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.

Authors:  Emilio A Emini; Wayne C Koff
Journal:  Science       Date:  2004-06-25       Impact factor: 47.728

2.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.

Authors:  V Usonis; S Meriste; V Bakasenas; I Lutsar; F Collard; M Stoffel; N Tornieporth
Journal:  Vaccine       Date:  2005-04-08       Impact factor: 3.641

4.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

5.  Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.

Authors:  Paolo Lusso; Patricia L Earl; Francesca Sironi; Fabio Santoro; Chiara Ripamonti; Gabriella Scarlatti; Renato Longhi; Edward A Berger; Samuele E Burastero
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.

Authors:  James M Binley; Charmagne S Cayanan; Cheryl Wiley; Norbert Schülke; William C Olson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

8.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

Authors:  W J Morrow; M Wharton; R B Stricker; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1986-09

9.  Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay.

Authors:  Lisa Cavacini; Marshall Posner
Journal:  AIDS Res Hum Retroviruses       Date:  2004-04       Impact factor: 2.205

10.  Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.

Authors:  Jeffrey D Lifson; Jeffrey L Rossio; Michael Piatak; Julian Bess; Elena Chertova; Douglas K Schneider; Vicky J Coalter; Barbara Poore; Rebecca F Kiser; Robert J Imming; Anthony J Scarzello; Louis E Henderson; W Gregory Alvord; Vanessa M Hirsch; Raoul E Benveniste; Larry O Arthur
Journal:  AIDS Res Hum Retroviruses       Date:  2004-07       Impact factor: 2.205

View more
  211 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

4.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

5.  Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure.

Authors:  Shang-Rung Wu; Robin Löving; Birgitta Lindqvist; Hans Hebert; Philip J B Koeck; Mathilda Sjöberg; Henrik Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

6.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.

Authors:  Nathan I Nicely; S Moses Dennison; Leonard Spicer; Richard M Scearce; Garnett Kelsoe; Yoshihiro Ueda; Haiyan Chen; Hua-Xin Liao; S Munir Alam; Barton F Haynes
Journal:  Nat Struct Mol Biol       Date:  2010-11-14       Impact factor: 15.369

8.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.

Authors:  Shuhei Nakane; Aikichi Iwamoto; Zene Matsuda
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

10.  Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Authors:  Wen Yuan; Xing Li; Marta Kasterka; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.